Sandoz and Samsung Bioepis Partner on Biosimilars

Sandoz Group AG has announced a partnership with Samsung Bioepis Co., Ltd., aiming to develop up to five biosimilars. The collaboration will enhance Sandoz's portfolio to potentially include 32 assets. Initially, a biosimilar to vedolizumab, used for conditions such as Crohn's disease, will be developed. Sandoz will hold exclusive global commercialization rights, excluding several Asian markets, while Samsung Bioepis will manage development and regulatory processes.

This agreement strengthens Sandoz's market presence in biosimilars and aligns with its strategy to capture a significant portion of the USD 320 billion market opportunity, projected due to biosimilar loss-of-exclusivity over ten years. This partnership follows the companies' successful collaborations on treatments like Pyzchiva® and Epysqli™.